379 related articles for article (PubMed ID: 10963503)
1. Tumor necrosis factor inactivation in the management of rheumatoid arthritis.
Baumgartner SW
South Med J; 2000 Aug; 93(8):753-9. PubMed ID: 10963503
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ; van de Putte LB; Breedveld FC
Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
[TBL] [Abstract][Full Text] [Related]
3. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
Jit M; Henderson B; Stevens M; Seymour RM
Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
[TBL] [Abstract][Full Text] [Related]
4. Biologics in rheumatoid arthritis.
Sharma PK; Hota D; Pandhi P
J Assoc Physicians India; 2004 Mar; 52():231-6. PubMed ID: 15636315
[TBL] [Abstract][Full Text] [Related]
5. Tumor necrosis factor inhibitors: new options for treating rheumatoid arthritis.
Moreland LW
Isr Med Assoc J; 2001 Sep; 3(9):686-90. PubMed ID: 11574988
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic agents for rheumatoid arthritis: infliximab (a chimeric human IgG 1 monoclonal antibody to TNF-alpha) and etanercept (a soluble form of human TNF type II receptor linked to an IgG 1-Fc moietry)].
Akiyama Y; Mimura T
Masui; 2006 Jul; 55(7):864-72. PubMed ID: 16856547
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.
Cairns AP; Taggart AJ
Ulster Med J; 2002 Nov; 71(2):101-5. PubMed ID: 12513005
[TBL] [Abstract][Full Text] [Related]
8. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
[TBL] [Abstract][Full Text] [Related]
9. Etanercept and infliximab for rheumatoid arthritis.
Drug Ther Bull; 2001 Jul; 39(7):49-52. PubMed ID: 11471515
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Jones RE; Moreland LW
Bull Rheum Dis; 1999; 48(3):1-4. PubMed ID: 10408141
[TBL] [Abstract][Full Text] [Related]
12. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
[TBL] [Abstract][Full Text] [Related]
13. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
15. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
Ang HT; Helfgott S
J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
[TBL] [Abstract][Full Text] [Related]
16. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
Mizutani W
Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
18. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity.
Tokayer A; Carsons SE; Chokshi B; Santiago-Schwarz F
J Rheumatol; 2002 Mar; 29(3):454-61. PubMed ID: 11908556
[TBL] [Abstract][Full Text] [Related]
19. Thrombogenicity of TNF alpha in rheumatoid arthritis defined through biological probes: TNF alpha blockers.
Ferraccioli G; Gremese E
Autoimmun Rev; 2004 Jun; 3(4):261-6. PubMed ID: 15246021
[TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
Guillevin L; Mouthon L
J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
[No Abstract] [Full Text] [Related]
[Next] [New Search]
